These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
890 related articles for article (PubMed ID: 31507204)
1. Perspectives on the Barrier to Resistance for Dolutegravir + Lamivudine, a Two-Drug Antiretroviral Therapy for HIV-1 Infection. Boffito M; Waters L; Cahn P; Paredes R; Koteff J; Van Wyk J; Vincent T; Demarest J; Adkison K; Quercia R AIDS Res Hum Retroviruses; 2020 Jan; 36(1):13-18. PubMed ID: 31507204 [TBL] [Abstract][Full Text] [Related]
2. Doing More With Less: Review of Dolutegravir-Lamivudine, a Novel Single-Tablet Regimen for Antiretroviral-Naïve Adults With HIV-1 Infection. Santevecchi BA; Miller S; Childs-Kean LM Ann Pharmacother; 2020 Dec; 54(12):1252-1259. PubMed ID: 32517480 [TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO Study. van Wyk J; Ajana F; Bisshop F; De Wit S; Osiyemi O; Portilla Sogorb J; Routy JP; Wyen C; Ait-Khaled M; Nascimento MC; Pappa KA; Wang R; Wright J; Tenorio AR; Wynne B; Aboud M; Gartland MJ; Smith KY Clin Infect Dis; 2020 Nov; 71(8):1920-1929. PubMed ID: 31905383 [TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Results Through Week 144 From the Phase 3, Noninferiority TANGO Randomized Trial. Osiyemi O; De Wit S; Ajana F; Bisshop F; Portilla J; Routy JP; Wyen C; Ait-Khaled M; Leone P; Pappa KA; Wang R; Wright J; George N; Wynne B; Aboud M; van Wyk J; Smith KY Clin Infect Dis; 2022 Sep; 75(6):975-986. PubMed ID: 35079789 [TBL] [Abstract][Full Text] [Related]
5. Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) From Dolutegravir (DTG)+F/TAF or DTG+F/Tenofovir Disoproxil Fumarate (TDF) in the Presence of Pre-existing NRTI Resistance. Acosta RK; Willkom M; Andreatta K; Liu H; Martin R; Parvangada A; Martin H; Collins S; White KL J Acquir Immune Defic Syndr; 2020 Nov; 85(3):363-371. PubMed ID: 32701823 [TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness and budget impact of dolutegravir/lamivudine for treatment of human immunodeficiency virus (HIV-1) infection in the United States. Butler K; Anderson SJ; Hayward O; Jacob I; Punekar YS; Evitt LA; Oglesby A J Manag Care Spec Pharm; 2021 Jul; 27(7):891-903. PubMed ID: 34185564 [No Abstract] [Full Text] [Related]
7. Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment-Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials. Cahn P; Madero JS; Arribas JR; Antinori A; Ortiz R; Clarke AE; Hung CC; Rockstroh JK; Girard PM; Sievers J; Man CY; Urbaityte R; Brandon DJ; Underwood M; Tenorio AR; Pappa KA; Wynne B; Gartland M; Aboud M; van Wyk J; Smith KY J Acquir Immune Defic Syndr; 2020 Mar; 83(3):310-318. PubMed ID: 31834000 [TBL] [Abstract][Full Text] [Related]
8. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. Walmsley SL; Antela A; Clumeck N; Duiculescu D; Eberhard A; Gutiérrez F; Hocqueloux L; Maggiolo F; Sandkovsky U; Granier C; Pappa K; Wynne B; Min S; Nichols G; N Engl J Med; 2013 Nov; 369(19):1807-18. PubMed ID: 24195548 [TBL] [Abstract][Full Text] [Related]
9. Health care resource utilization and costs for treatment-experienced people with HIV switching or restarting antiretroviral regimens since 2018. Colson A; Chastek B; Gruber J; Majethia S; Zachry W; Mezzio D; Rock M; Anderson A; Cohen JP J Manag Care Spec Pharm; 2024 Aug; 30(8):817-824. PubMed ID: 39088337 [TBL] [Abstract][Full Text] [Related]
10. Impact of switching to TAF/FTC/RPV, TAF/FTC/EVG/cobi and ABC/3TC/DTG on cardiovascular risk and lipid profile in people living with HIV: a retrospective cohort study. Giacomelli A; Conti F; Pezzati L; Oreni L; Ridolfo AL; Morena V; Bonazzetti C; Pagani G; Formenti T; Galli M; Rusconi S BMC Infect Dis; 2021 Jun; 21(1):595. PubMed ID: 34157984 [TBL] [Abstract][Full Text] [Related]
11. Brief Report: Improvement in Metabolic Health Parameters at Week 48 After Switching From a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen to the 2-Drug Regimen of Dolutegravir/Lamivudine: The TANGO Study. van Wyk J; Ait-Khaled M; Santos J; Scholten S; Wohlfeiler M; Ajana F; Jones B; Nascimento MC; Tenorio AR; Smith DE; Wright J; Wynne B J Acquir Immune Defic Syndr; 2021 Jun; 87(2):794-800. PubMed ID: 33587500 [TBL] [Abstract][Full Text] [Related]
12. Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy - naive adults with HIV-1 infection. Cahn P; Sierra Madero J; Arribas JR; Antinori A; Ortiz R; Clarke AE; Hung CC; Rockstroh JK; Girard PM; Sievers J; Man CY; Urbaityte R; Brandon DJ; Underwood M; Pappa KA; Curtis L; Smith KY; Gartland M; Aboud M; van Wyk J; Wynne B AIDS; 2022 Jan; 36(1):39-48. PubMed ID: 34534138 [TBL] [Abstract][Full Text] [Related]
13. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. Cahn P; Madero JS; Arribas JR; Antinori A; Ortiz R; Clarke AE; Hung CC; Rockstroh JK; Girard PM; Sievers J; Man C; Currie A; Underwood M; Tenorio AR; Pappa K; Wynne B; Fettiplace A; Gartland M; Aboud M; Smith K; Lancet; 2019 Jan; 393(10167):143-155. PubMed ID: 30420123 [TBL] [Abstract][Full Text] [Related]
14. Dolutegravir + Lamivudine vs. Dolutegravir + Tenofovir Disoproxil Fumarate/Emtricitabine: Very-Low-Level HIV-1 Replication through 144 Weeks in the GEMINI-1 and GEMINI-2 Studies. Underwood M; Urbaityte R; Wang R; Horton J; Oyee J; Wynne B; Fox D; Jones B; Man C; Sievers J Viruses; 2024 Mar; 16(3):. PubMed ID: 38543770 [TBL] [Abstract][Full Text] [Related]
15. Dolutegravir Plus Lamivudine as Initial Therapy for HIV-1 Infected and ARV-naïve Patients in West China, 24-Weeks Results of a Preliminary Real-world Study. Hui X; Gan X; Li Q; Sun W Curr HIV Res; 2022; 20(3):222-227. PubMed ID: 35570525 [TBL] [Abstract][Full Text] [Related]
16. Dolutegravir plus lamivudine versus efavirenz plus tenofovir disoproxil fumarate and lamivudine in antiretroviral-naive adults with HIV-1 infection. Deng L; Li C; Chen P; Luo X; Zheng X; Zhou L; Zhou Y; Xia J; Hong Z BMC Infect Dis; 2022 Jan; 22(1):17. PubMed ID: 34983415 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Switching to the 2-Drug Regimen Dolutegravir/Lamivudine Versus Continuing a 3- or 4-Drug Regimen for Maintaining Virologic Suppression in Adults Living With Human Immunodeficiency Virus 1 (HIV-1): Week 48 Results From the Phase 3, Noninferiority SALSA Randomized Trial. Llibre JM; Brites C; Cheng CY; Osiyemi O; Galera C; Hocqueloux L; Maggiolo F; Degen O; Taylor S; Blair E; Man C; Wynne B; Oyee J; Underwood M; Curtis L; Bontempo G; van Wyk J Clin Infect Dis; 2023 Feb; 76(4):720-729. PubMed ID: 35235656 [TBL] [Abstract][Full Text] [Related]
18. Abacavir/dolutegravir/lamivudine single-tablet regimen: a review of its use in HIV-1 infection. Greig SL; Deeks ED Drugs; 2015 Apr; 75(5):503-14. PubMed ID: 25698454 [TBL] [Abstract][Full Text] [Related]
19. HIV 101: fundamentals of antiretroviral therapy. Saag MS Top Antivir Med; 2019 Sep; 27(3):123-127. PubMed ID: 31634859 [TBL] [Abstract][Full Text] [Related]
20. Comparative efficacy and safety and dolutegravir and lamivudine in treatment naive HIV patients. Radford M; Parks DC; Ferrante S; Punekar Y AIDS; 2019 Sep; 33(11):1739-1749. PubMed ID: 31180906 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]